The current generation of anti-cancer agents, often referred to as molecularly targeted therapies, are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. This review focuses on these therapies, particularly as many of the drugs concerned have received considerable attention in the popular media.
Get full access to this article
View all access options for this article.
References
1.
HanahanDWeinbergRA.The hallmarks of cancer. Cell2000; 100:57–70.
2.
AaronsonSA.Growth factors and cancer. Science 1991; 254: 1146–53.
3.
HaoDRowinskyEK.Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and ras inhibitors. Cancer Invest2002; 20:387–404.
4.
SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001; 344:783–92.
5.
Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005; 353:1659–72.
6.
GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol2004; 22:777–84.
7.
LlovetJMRicciSMazzaferroV, Sorafenib in advanced hepatocellular carcinoma. New Engl J Med2008; 359:378–90.
8.
MidgleyRKerrD.Bevacizumab – current status and future directions. Ann Oncol2005; 16:999–1004.
9.
UllrichASchlessingerJ.Signal transduction by receptors with tyrosine kinase activity. Cell1990; 61:203–12.
10.
DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med2001; 344:1031–7.
11.
LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med2004; 350:2129–39.
12.
JonesPABaylinSB.The fundamental role of epigenetic events in cancer. Nat Rev Genet2002; 3:415–28.
13.
EvansJChitnisMMTalbotDC.Principles of chemotherapy and drug development. In Price P, Sikora K, Illidge T, editors. Treatment of cancer (5th edition). London: Arnold; 2008. p.75–111.
